The effects of a relatively new antidepressant drug, fluvoxamine, were compared with those produced by chlorimipramine on the 5-hydroxytryptamine system in rat brain. Daily treatment with fluvoxamine (25 mg/kg, i.p.) and an equivalent dose of chlorimipramine (28 mg/kg, i.p.) for 7 days reduced (3H)5-hydroxytryptamine uptake by crude synaptosomes (P2 pellet) of brain to 56 and 45 %, respectively, but produced no change in midbrain monoamine oxidase activity. Repeated administration of these drugs significantly decreased tryptophan hydroxylase activity as well as tryptophan level in the midbrain region. The concentration of 5-hydroxyindoleacetic acid also was lowered in several discrete areas of the brain, but no change was seen in the endogenous levels of 5-hydroxytryptamine. Our data suggest that fluvoxamine, like chlorimipramine, is a potent inhibitor of 5-hydroxytryptamine uptake. Unlike tricyclic antidepressants, fluvoxamine does not seem to produce any sedation in animals, which was evidenced by no significant change in spontaneous locomotor activity.

Keywords:
Fluvoxamine, Brain serotonergic system
This content is only available via PDF.
© 1983 S. Karger AG, Basel
1983
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.